The GlucoSet management team combines clinical insight with start-up and scale-up experience.


All stock in GlucoSet is owned by the employees, board members and the company's largest investor, Televenture Management.


Our advisory board is hand-picked with international experts that give valuable external input on external issues. 


Peter Nissen Jørgensen is former VP for business development of Novo Nordisk AS, a big player in the diabetes market. He has more than 20 years experience with medtech business development and is now Senior Consultant at the Danish medtech management consultancy firm, tto AS.

Marcus Schultz, MD PhD is a professor in experimental intensive care medicine at the University of Amsterdam, and is involved in implementation of new strategies and technologies in modern ICUs. He has co-authored more than 300 published papers. 

Fedrico Bilotta, MD PhD is a recognized anasthesiologist working within critical care and pain medicine at the 'Sapienza' University of Rome and has published more than 70 papers in recognized journals, among other things on glycemic control in the ICU.


GlucoSet has been supported directly or through the Norwegian University of Science and Technology by the following entities: